Drug & intervention

naltrexone

RxCUI 7243

Clinical trials27
Recruiting2
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Naltrexone

Naltrexone, sold under the brand name Revia among others, is a medication primarily used to manage alcohol use and opioid use disorders by reducing cravings and feelings of euphoria associated with substance use disorder. It has also been found to be effective for the treatment of other addictions and may be used for them off-label. The combination naltrexone/bupropion is used to treat obesity. Naltrexone is an opioid antagonist and works by blocking the effects of opioids, including both opioid drugs as well as opioids naturally produced in the brain. It is taken orally or by injection into a muscle. Effects begin within 30 minutes, though a decreased desire for opioids may take a few weeks to occur. Side effects may include trouble sleeping, anxiety, nausea, and headaches. In those still on opioids, opioid withdrawal may occur. Use is not recommended in people with liver failure. It is unclear if use is safe during pregnancy. Naltrexone was first made in 1965 and was approved for medical use in the United States in 1984. It is on the WHO Model List of Essential Medicines. In 2021, it was the 254th most commonly prescribed medication in the United States, with more than 1 million prescriptions.

Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

27 shown
Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)NCT07224009 · 2026-08-25
RECRUITING
Low-Dose Naltrexone for the Treatment of Painful Diabetic NeuropathyNCT04678895 · 2020-12-22
RECRUITING
Glutamate and Opioid Mechanisms of Antidepressant Response to KetamineNCT04977674 · 2021-09-27
COMPLETED
Rapid Antidepressant Improvement Secondary to Excitatory Brain ResponsesNCT04276259 · 2020-10-19
COMPLETED
Low Dose Naltrexone for Chronic Pain in Osteoarthritis and Inflammatory ArthritisNCT04115020 · 2020-01-01
WITHDRAWN
Low Dose Naltrexone for Chronic Pain From ArthritisNCT03008590 · 2018-05-01
COMPLETED
Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in SchizophreniaNCT03132571 · 2017-06-01
TERMINATED
Naltrexone and Bupropion Combination on Obese,Smoking Patients With SchizophreniaNCT02736474 · 2016-05-01
COMPLETED
Better Than Study: Targeting Heavy Alcohol Use With Naltrexone Among Men Who Have Sex With Men (MSM)NCT02330419 · 2015-04-01
COMPLETED
Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast CancerNCT02137252 · 2014-05-01
TERMINATED
Low-Dose Naltrexone (LDN) for Depression Relapse and RecurrenceNCT01874951 · 2013-06-01
COMPLETED
Naltrexone for Antipsychotic-Induced Weight GainNCT01866098 · 2013-05-01
COMPLETED
Clinical Trial to Reduce Drinking in Women With HIVNCT01625091 · 2012-12-01
COMPLETED
Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal CancerNCT01650350 · 2012-11-01
TERMINATED
Extended-Release Naltrexone to Treat Methamphetamine Dependence in Men Who Have Sex With Men (MSM)NCT01449565 · 2012-09-01
COMPLETED
Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and PreventionNCT01227044 · 2011-04-01
COMPLETED
Stress, Hormones, and EatingNCT01175512 · 2010-07-01
COMPLETED
Naltrexone for Impulse Control Disorders in Parkinson's DiseaseNCT01052831 · 2009-11-01
COMPLETED
Naltrexone and Hypoglycemia in Type 1 DiabetesNCT01053078 · 2009-10-01
COMPLETED
Pharmacotherapy for HIV Infected Patients With Alcohol ProblemsNCT00854230 · 2009-01-01
WITHDRAWN
Effectiveness Study Low-Dose Naltrexone Versus ARV's for HIV+NCT01174914 · 2008-03-01
COMPLETED
A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose NaltrexoneNCT00501696 · 2007-02-01
COMPLETED
Augmenting Zyprexa With Naltrexone to Ameliorate Metabolic Side-EffectsNCT00567034 · 2006-12-01
COMPLETED
Phase II of Naltrexone in Hormone-Refractory Metastatic Breast CancerNCT00379197 · 2006-07-01
TERMINATED
HIV Risk Reduction and Drug Abuse Treatment in IranNCT00398008 · 2004-10-01
WITHDRAWN
HIV Risk Reduction and Drug Abuse Treatment in MalaysiaNCT00383045 · 2003-04-01
COMPLETED
Treating Alcohol Use In Older Adults With DepressionNCT00018824 · 1999-10-01
COMPLETED

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.